May 29, 2019:
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) CEO
Robert Sutton today congratulated the Governor and Legislature of
Colorado for their passage of an historic bill allowing physicians
to recommend cannabis instead of opioids for relief of
pain.
“Colorado is the first state in the US, and among very few
governments around the world, that has recognized the potential of
cannabis to deal with chronic or acute pain,” said Sutton. “This is
a courageous and critical first step in battling the epidemic of
opioid deaths we have suffered in the United States.”
Colorado Governor Jared Polis signed Senate Bill 13 on Thursday
as the State wrestles with the growing problem of opioid addiction.
Currently physicians can prescribe medical marijuana for patients
suffering from cancer, glaucoma, HIV and AIDS, PTSD, or other
chronic disorders that cause severe pain, seizures and nausea.
When the law takes effect on Aug. 2 this year, physicians will
have the option of prescribing cannabis for any medical condition
for which opioids are currently prescribed.
“The state government is not telling doctors they have to
replace opioids with cannabis, but rather, they are endorsing the
idea that doctors should be given the latitude to use cannabis for
treatment, rather than opting for opioids, which are much more
addictive and much more likely to result in a fatal overdose,”
explained NanoSphere Chief Science Officer Richard
Kaufman.
“This falls in line with all of our own research, much of which
has been in the area of replacing opioids with cannabinoids for the
treatment of severe and chronic pain.”
NanoSphere’s patented lipid nanoparticles efficiently
encapsulate and effectively delivery therapeutic dosages of full
spectrum cannabis oil extracts for relieving acute, chronic and
neurogenic pain and inflammation through different routes of
administration. They include transdermal, intranasal and intraoral
delivered Nanosphere products. NanoSphere’s transdermal NanoSerum
is currently sold through a network of dispensaries in Colorado and
California.
“We have already seen significant results with our transdermal
NanoSerum in clinical observations of patients with very severe,
acute pain, and some people have stopped using opioids and have
replaced them with our product, which is not addictive, and is free
of any serious side effects,” said Kaufman. “What has been missing
to date is the endorsement of government and the medical community
that cannabinoids can, in fact, act as a viable alternative to
opioids.”
Kaufman points out there is a large and growing body of evidence
that medical cannabis can act as a substitute or an adjunct to
prescription opiates in the treatment of chronic and acute
pain.
A recent study in the Clinical Journal of Pain followed 176
patients with chronic pain in Israel, and found that 44 per cent of
them stopped taking prescription opioids within seven months of
starting use of medical cannabis. Patients cited several reasons
for preferring cannabis over prescription drugs, with 65 per cent
reporting fewer adverse side effects, 57 per cent citing better
management of symptoms, and 34 per cent saying cannabis had far
less potential for withdrawal issues. (Haroutounian S, et al: The
Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes
in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 2016
Dec;32(12):1036-1043)
“No one is claiming that cannabis can treat everything, or that
it’s the right choice for every person suffering from severe pain,
but what we believe and what the Colorado government has endorsed,
is that proper application of medical cannabis can help reduce our
society’s reliance on more addictive, more dangerous medicines,”
said Sutton. “Colorado has taken an historic step forward, and we
expect to be part of the solution as doctors and patients explore
healthier alternatives to opioid=based therapies.”
On behalf of the Board
David Sutton, President and COO
720.520.4283
dsutton@nanospherehealth.com
Investor Contact:
Victor Goncalves, Executive Vice President
Mobile: 204-997-5517
E-mail: vgoncalves@nanospherehealth.com
About NanoSphere
NanoSphere Health Sciences LLC, is a biotechnology firm
specializing in the creation of the NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of
supplements, nutraceuticals and over-the-counter medications for
the cannabis, pharmaceutical and animal health industries, and
beyond. For more information on NanoSphere, please visit
http://www.nanospherehealth.com.
About Evolve Formulas
Evolve Formulas is the provider of the world's first and only
scientifically proven nanoparticle delivery system in cannabis.
Evolve’s pioneering product, Transdermal NanoSerum™, is a
fast-acting, ultra-strength transdermal formula infused with
nano-encapsulated cannabis and cannabis extracts. For more
information on Evolve Formulas, visit
https://www.evolveformulas.com/. Follow us on Facebook, Instagram
and Twitter.
The Canadian Securities Exchange does not accept responsibility
for the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this
news release which are not purely historical are forward looking
statements, including without limitation any statements concerning
the Company's intentions, plans, estimates, expectations or beliefs
regarding the future. Although the Company believes that any
forward looking statements in this news release are reasonable,
there can be no assurance that any such forward looking statements
will prove to be accurate. The Company cautions readers that all
forward looking statements, including without limitation those
relating to the Company's future operations and business prospects,
are based on assumptions none of which can be assured, and are
subject to certain risks and uncertainties that could cause actual
events or results to differ materially from those indicated in the
forward looking statements. Without limitation, these include
assumptions, risks and uncertainties inherent in completing
sub-licensing arrangements in the United States, Canada and abroad,
product demand, production, competition and government regulation
of the Cannabis industry, any and all of which may have an adverse
effect on the Company’s expansion plans, sales, revenues and its
financial results and condition. Readers are advised to rely
on their own evaluation of such risks and uncertainties and should
not place undue reliance on forward looking statements. Any forward
looking statements are made as of the date of this news release,
and the Company assumes no obligation to update the forward looking
statements, or to update the reasons why actual events or results
could or do differ from those projected in the forward looking
statements, whether as a result of new information, future events
or otherwise.
Kate Wells
NanoSphere Health Sciences
(303) 324-7358
kwells@nanospherehealth.com
NanoSphere Health Sciences (CSE:NSHS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
NanoSphere Health Sciences (CSE:NSHS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
